Loading
Loading
Research Overview
Potent ERRα/γ (oestrogen-related receptor) agonist; activates oxidative metabolism gene programs mimicking aspects of endurance exercise, increasing fat oxidation and mitochondrial biogenesis in skeletal muscle in rodent models.
SLU-PP-332 functions as an agonist at ERRα and ERRγ, constitutively active transcriptional regulators of mitochondrial and oxidative metabolic gene networks. Preclinical research has used this compound to investigate how pharmacological activation of ERR signalling influences mitochondrial biogenesis, skeletal muscle oxidative capacity, and energy metabolism in animal models.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, slu-pp-332 (errα/errγ agonist) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
SLU-PP-332 (ERRα/ERRγ Agonist) research is most relevant to protocols examining:
Exercise-mimetic and ERR receptor agonism research
Mitochondrial biogenesis and fat oxidation mechanism studies
Researchers investigating metabolic programming independent of physical training
Comparative ERR agonism studies with other exercise-mimetics
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Potent ERRα/γ (oestrogen-related receptor) agonist; activates oxidative metabolism gene programs mimicking aspects of endurance exercise, increasing fat oxidation and mitochondrial biogenesis in skeletal muscle in rodent models.
| Parameter | Value |
|---|---|
| Dose range | Under investigation |
| Schedule | Daily |
| Route | Subcutaneous, Oral (limited bioavailability) |
| Half-life | ~Hours |
primarily rodent studies
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
